share_log

Rodman & Renshaw Initiates Coverage On Mural Oncology With Buy Rating, Announces Price Target of $15

Benzinga ·  Jun 29 00:47

Rodman & Renshaw analyst Tony Butler initiates coverage on Mural Oncology (NASDAQ:MURA) with a Buy rating and announces Price Target of $15.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment